Rapid detection of the known SNPs of CYP2C9 using oligonucleotide microarray

World Journal of Gastroenterology

Volumn 9, Issue 6, 2003, Pages 1342-1346

  Wen, Si Yuan ^a   Wang, Hui ^a   Sun, Ou Jun ^a   Wang, Sheng Qi ^a  

^a BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C9; DNA; IRBESARTAN;

ALLELE; ARTICLE; ASSAY; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; DNA MICROARRAY; DNA SEQUENCE; DRUG EFFICACY; DRUG METABOLISM; ENZYME POLYMORPHISM; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MUTANT; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; RELIABILITY; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL ANALYSIS; TREATMENT OUTCOME; WILD TYPE;

EID: 0037713608     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v9.i6.1342     Document Type: Article

References (30)

1. Nebert DW, Mckinnon RA, Puga A. Human drug-metabolizing enzyme polymorphism: Effects on risk toxicity and cancer. DNA Cell Biol 1996; 15: 273-280
2. Shi MM, Bleavins MR, De La Iglesia FA. Pharmacogenetic application in drug development and clinical trials. Drug Metabolism Disposition 2001; 29: 591-595
3. Krynetski EY, Evans WE. Genetic polymorphism of thiopurine S-methyltransferase: Molecular mechanism and clinical importance. Pharmacology 2001; 61: 136-146
4. Cronin MT, Pho M, Dutta D, Frueh F, Schwarcz L, Brennan T. Utilization of new technologies in drug trials and discovery. Drug Metabolism Disposition 2001; 29: 586-590
5. Shi MM. Enabling large-scale pharmacogenetics studies by high-throughput mutation detection and genotyping technologies. Clini Chem 2001; 47: 164-172
6. Broude NE, Woodward K, Cavallo R, Cantor CR, Englert D. DNA microarrays with stem-loop DNA probe: Preparations and applications. Nucleic Acids Research 2001; 29: E92
7. Zhu GJ, Yu YN, Li X, Qian YL. Cloning of cytochrome P-450 2C9 cDNA from human liver and its expression in CHL cells. World J Gastroenterol 2002; 8: 318-322
8. Cai L, Yu SZ, Zhan ZF. Cytochrome P450 2E1 genetic polymorphism and gastric cancer in Changle, Fujian Province. World J Gastroenterol 2001; 7: 792-795
9. Cheng JW. Cytochrome p450-mediated cardiovascular drug interactions. Heart Dis 2000; 2: 254-258
10. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353: 717-719
11. Kidd RS, Curry TB, Gallagher S, Edeki T, Blaisdell J, Goldstein JA. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics 2001; 11: 803-808
12. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol. 2001; 52: 349-355
13. Timmermans PB. Pharmacological properties of angiotensin II receptor antagonists. Can J Cardo 1999; 15(Suppl. F): 26F-28F
14. Graham MR, Allcock NM. Irbesartan substitution for valsartan or losartan in treating hypertension. Ann Pharmacother 2002; 36: 1840-1844
15. Yasar U, Tybring G, Hidestrand M, Oscarson M, Ingelman-Sundberg M, Dahl ML, Eliasson E. Role of CYP2C9 polymorphism in losartan oxidation. Drug Metab Dispos 2001; 29: 1051-1056
16. Li T, Liang H, Yan F, Lu S. Site-directed mutagenesis of atrial natriuretic peptide gene and effect of the mutations on its diuretic activity in nephrotic rats. Zhonghua Yixue Zazhi 2002; 82: 1324-1327
17. Yoon YR, Shon JH, Kim MK, Lim YC, Lee HR, Park JY, Cha IJ, Shin JG. Frequency of cytochrome P450 2C9 mutant alleles in a Korean population. Br J Clin Pharmacol 2001; 51: 277-280
18. Dickmann LJ, Rettie AE, Kneller MB, Kim RB, Wood AJ, Stein CM. Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African American. Mol Pharmacol 2001; 60: 382-387
19. Gu HF. Single nucleotide polymorphisms (SNPs) and SNP databases. Zhonghua Yixue Yichuanxue Zazhi 2001; 18: 479-481
20. Kwok PY. Methods for genotyping single nucleotide polymorphisms. Annu Rev Genomics Hum Genet 2001; 2: 235-258
21. Roses AD. Pharmacogenetics. Hum Mol Genet 2001; 10: 2261-2267
22. Hsieh KP, Lin YY, Cheng CL, Lai ML, Lin MS, Siest JP, Huang JD. Novel mutations of CYP3A4 in Chinese. Drug Metab Dispos 2001; 29: 268-273
23. Oda Y, Kobayashi M, Ooi A, Muroishi Y, Nakanishi I. Genotypes of glutathione S-transferase M1 and N-acetyltransferase 2 in Japanese patients with gastric cancer. Gastric Cancer 1999; 2: 158-164
24. Hersberger M, Marti-Jaun J, Rentsch K, Hanseler E. Rapid detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 alleles by tetra-primer PCR and of the CYP2D6*5 allele by multiplex long PCR. Clin Chem 2000; 46: 1072-1077
25. Li JJ, Geyer R, Tan W. Using molecular beacons as a sensitive fluorescence assay for enzymatic cleavage of single-stranded DNA. Nucleic Acids Res 2000; 28: E52
26. Kleiber J, Walter T, Haberhausen G, Tsang S, Babiel R, Rosenstraus M. Performance characteristics of a quantitative, homogeneous TaqMan RT-PCR test for HCV RNA. J Mol Diagn 2000; 2: 158-166
27. O'Meara D, Ahmadian A, Odeberg J, Lundeberg J. SNP typing by apyrase-mediated allele-specific primer extension on DNA microarrays. Nucleic Acids Res 2002; 30 e75
28. Iwasaki H, Ezura Y, Ishida R, Kajita M, Kodaira M, Knight J, Daniel S, Shi M, Emi M. Accuracy of genotyping for single nucleotide polymorphisms by a microarray-based single nucleotide polymorphism typing method involving hybridization of short allele-specific oligonucleotide. DNA Res 2002; 9: 59-62
29. Huber M, Mundlein A, Dornstauder E, Schneeberger C, Tempfer CB, Mueller MW, Schmidt WM. Accessing single nucleotide polymorphisms in genomic DNA by direct multiplex polymerase chain reaction amplification on oligonucleotide microarrays. Anal Biochem 2002; 303: 25-33
30. Bertilsson L, Geographical/interracial difference in polymorphic drug oxidation. Clin Pharmacokinet 1995; 29: 192-209